Why the study?
Certain gene polymorphisms are known to affect responsiveness to aspirin and clopidogrel DAPT, prompting investigation of DAPT non-responsiveness and its genetic associations in MI patients.
Are genetic polymorphisms associated with aspirin and clopidogrel non-responsiveness in patients with myocardial infarction?
Are genetic polymorphisms associated with aspirin and clopidogrel non-responsiveness in patients with myocardial infarction?
Genetic polymorphisms, specifically CYP2C19*2 G>A and GPVI T>C, are significantly associated with non-responsiveness to aspirin and clopidogrel in patients with myocardial infarction.
Answers are grounded in this paper and cite their sources.
Does not support routine genotyping for DAPT non-responsiveness in MI; leaves open prospective validation of CYP2C19 and GPVI variants.
Background & objectives: Cytochrome P450, P2Y12, cyclooxygenase-1 (COX1) and glycoprotein V1 (GPVI) gene polymorphisms are known to affect patient responsiveness towards aspirin and clopidogrel dual antiplatelet therapy (DAPT). The present study was undertaken to identify aspirin and clopidogrel non-responsiveness and its association with genetic polymorphism in patients with myocardial infarction (MI). Methods: A total of 207 MI patients who were on DAPT, were included. The DAPT non-responsiveness was determined by light transmittance aggregometry using arachidonic acid and adenosine diphosphate and high platelet reactivity by collagen. Platelet activation biomarkers, thromboxane B2 (TxB2) and soluble CD40 ligand (sCD40L) were measured in plasma. Patient compliance was checked by estimating drug and its metabolite levels (aspirin and clopidogrel) in plasma using liquid chromatography-mass spectrometry/mass spectrometry. Genomic DNA was extracted, amplified by polymerase chain reaction and subsequently sequenced to identify CYP450, P2Y12, COX1 and GPVI gene polymorphisms. Results: Of the 207 patients, 32 were non-responders. The DAPT non-responsiveness was found in 15.5 per cent patients. The non-responsiveness showed a significant and an independent association with gender [odds ratio (OR)=0.18, 95% confidence interval (CI)=0.01-0.78, P=0.023], TxB2 (OR=1.00, 95% CI=1.00-1.01, P=0.013), CYP2C19*2 G>A (OR=3.33, 95% CI=1.04-10.69, P=0.044) and GPVI T>C (OR=0.23, 95% CI=0.08-0.67, P=0.007) after adjusting the demographic, clinical and genetic confounding factors when assessed between non-responder and responder compliant patients. Interpretation & conclusions: The study showed a significant association of genetic polymorphisms (CYP2C19*2 G>A and GPVI T>C) with DAPT non-responsiveness in MI patients. The findings of this study need further validation in a large cohort of patients with clinical follow up.
No takes yet. Share an insight, caveat, or question.
Misra et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: